Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PSTX |
---|---|---|
09:32 ET | 12134 | 9.3699 |
09:33 ET | 6685 | 9.3625 |
09:35 ET | 2435 | 9.36 |
09:37 ET | 5618 | 9.3571 |
09:39 ET | 8045 | 9.36 |
09:42 ET | 600 | 9.36 |
09:44 ET | 8917 | 9.3716 |
09:46 ET | 2000 | 9.38 |
09:48 ET | 9587 | 9.375 |
09:50 ET | 1453 | 9.375 |
09:51 ET | 10680 | 9.38 |
09:53 ET | 1683 | 9.38 |
09:55 ET | 910 | 9.38 |
09:57 ET | 2882 | 9.375 |
10:00 ET | 1500 | 9.375 |
10:02 ET | 27766 | 9.385 |
10:04 ET | 800 | 9.39 |
10:06 ET | 4142 | 9.39 |
10:08 ET | 2689 | 9.39 |
10:09 ET | 15097 | 9.38 |
10:11 ET | 914 | 9.375 |
10:13 ET | 4252 | 9.375 |
10:15 ET | 4945 | 9.375 |
10:18 ET | 7118 | 9.38 |
10:20 ET | 1824 | 9.375 |
10:22 ET | 2800 | 9.38 |
10:24 ET | 8587 | 9.375 |
10:26 ET | 1000 | 9.37 |
10:27 ET | 800 | 9.37 |
10:29 ET | 800 | 9.375 |
10:31 ET | 12485 | 9.3775 |
10:33 ET | 2637 | 9.38 |
10:36 ET | 1028 | 9.38 |
10:38 ET | 2354 | 9.38 |
10:40 ET | 2714 | 9.38 |
10:42 ET | 1651 | 9.375 |
10:44 ET | 2400 | 9.38 |
10:45 ET | 1100 | 9.375 |
10:47 ET | 4878 | 9.39 |
10:49 ET | 6300 | 9.385 |
10:51 ET | 2377 | 9.385 |
10:54 ET | 100 | 9.385 |
10:56 ET | 1300 | 9.38 |
10:58 ET | 200 | 9.385 |
11:00 ET | 2074 | 9.385 |
11:02 ET | 1238 | 9.39 |
11:03 ET | 2886 | 9.385 |
11:05 ET | 700 | 9.385 |
11:07 ET | 2100 | 9.385 |
11:09 ET | 300 | 9.385 |
11:12 ET | 756 | 9.385 |
11:14 ET | 3766 | 9.385 |
11:16 ET | 400 | 9.38 |
11:18 ET | 1750 | 9.3801 |
11:20 ET | 730 | 9.385 |
11:21 ET | 200 | 9.385 |
11:23 ET | 200 | 9.39 |
11:25 ET | 1808 | 9.39 |
11:27 ET | 300 | 9.385 |
11:30 ET | 400 | 9.38 |
11:32 ET | 300 | 9.38 |
11:34 ET | 800 | 9.39 |
11:36 ET | 100 | 9.39 |
11:38 ET | 100 | 9.39 |
11:39 ET | 100 | 9.385 |
11:41 ET | 200 | 9.39 |
11:43 ET | 1168 | 9.385 |
11:45 ET | 3100 | 9.39 |
11:48 ET | 1612 | 9.38 |
11:50 ET | 800 | 9.385 |
11:52 ET | 800 | 9.385 |
11:54 ET | 970 | 9.385 |
11:56 ET | 1100 | 9.385 |
11:57 ET | 637 | 9.39 |
11:59 ET | 1800 | 9.385 |
12:01 ET | 1300 | 9.38 |
12:03 ET | 550 | 9.39 |
12:06 ET | 2196 | 9.39 |
12:08 ET | 1221 | 9.3818 |
12:10 ET | 28868 | 9.395 |
12:12 ET | 1700 | 9.4 |
12:14 ET | 600 | 9.4 |
12:15 ET | 600 | 9.395 |
12:17 ET | 4691 | 9.4 |
12:19 ET | 1866 | 9.4 |
12:21 ET | 3733 | 9.4 |
12:24 ET | 3354 | 9.4 |
12:26 ET | 1135 | 9.4 |
12:28 ET | 500 | 9.4 |
12:30 ET | 569 | 9.4 |
12:32 ET | 1714 | 9.3907 |
12:33 ET | 100 | 9.4 |
12:35 ET | 4464 | 9.4 |
12:37 ET | 2600 | 9.4 |
12:39 ET | 2261 | 9.4 |
12:42 ET | 875 | 9.4 |
12:44 ET | 300 | 9.4 |
12:46 ET | 100 | 9.4 |
12:48 ET | 200 | 9.4 |
12:50 ET | 1700 | 9.3918 |
12:51 ET | 200 | 9.395 |
12:53 ET | 637 | 9.394 |
12:55 ET | 200 | 9.4 |
12:57 ET | 1000 | 9.395 |
01:00 ET | 1716 | 9.395 |
01:02 ET | 1004 | 9.4 |
01:04 ET | 400 | 9.4 |
01:06 ET | 500 | 9.4 |
01:08 ET | 6222 | 9.4 |
01:09 ET | 22635 | 9.395 |
01:11 ET | 22437 | 9.385 |
01:13 ET | 388 | 9.385 |
01:15 ET | 500 | 9.39 |
01:18 ET | 1256 | 9.385 |
01:20 ET | 200 | 9.38 |
01:22 ET | 200 | 9.39 |
01:24 ET | 300 | 9.385 |
01:27 ET | 684 | 9.38 |
01:29 ET | 200 | 9.39 |
01:31 ET | 100 | 9.385 |
01:33 ET | 2200 | 9.385 |
01:36 ET | 1604 | 9.385 |
01:38 ET | 383 | 9.39 |
01:40 ET | 611 | 9.39 |
01:42 ET | 4403 | 9.385 |
01:44 ET | 300 | 9.38 |
01:45 ET | 200 | 9.385 |
01:47 ET | 1800 | 9.39 |
01:49 ET | 309 | 9.39 |
01:51 ET | 8639 | 9.38 |
01:54 ET | 400 | 9.38 |
01:56 ET | 200 | 9.38 |
02:00 ET | 509 | 9.39 |
02:02 ET | 100 | 9.39 |
02:03 ET | 32182 | 9.37 |
02:05 ET | 2300 | 9.37 |
02:07 ET | 500 | 9.375 |
02:09 ET | 1199 | 9.37 |
02:12 ET | 800 | 9.375 |
02:14 ET | 9286 | 9.375 |
02:16 ET | 15061 | 9.375 |
02:18 ET | 1883 | 9.38 |
02:20 ET | 500 | 9.38 |
02:21 ET | 1500 | 9.38 |
02:23 ET | 996 | 9.375 |
02:25 ET | 611 | 9.375 |
02:27 ET | 200 | 9.38 |
02:30 ET | 734 | 9.38 |
02:32 ET | 789 | 9.375 |
02:34 ET | 42807 | 9.375 |
02:36 ET | 5030 | 9.375 |
02:38 ET | 975 | 9.375 |
02:39 ET | 2356 | 9.37 |
02:41 ET | 700 | 9.375 |
02:43 ET | 601 | 9.37 |
02:45 ET | 915 | 9.37 |
02:48 ET | 600 | 9.37 |
02:50 ET | 1266 | 9.37 |
02:52 ET | 400 | 9.37 |
02:54 ET | 600 | 9.375 |
02:56 ET | 1500 | 9.38 |
02:57 ET | 400 | 9.375 |
02:59 ET | 1838 | 9.375 |
03:01 ET | 700 | 9.37 |
03:03 ET | 705 | 9.375 |
03:06 ET | 650 | 9.375 |
03:08 ET | 100 | 9.375 |
03:10 ET | 2894 | 9.38 |
03:12 ET | 400 | 9.375 |
03:14 ET | 507 | 9.38 |
03:15 ET | 1200 | 9.38 |
03:17 ET | 200 | 9.38 |
03:19 ET | 300 | 9.38 |
03:21 ET | 400 | 9.37 |
03:24 ET | 513 | 9.375 |
03:26 ET | 1027 | 9.38 |
03:28 ET | 5571 | 9.38 |
03:30 ET | 1428 | 9.38 |
03:32 ET | 1529 | 9.375 |
03:33 ET | 1683 | 9.38 |
03:35 ET | 828 | 9.38 |
03:37 ET | 1069 | 9.38 |
03:39 ET | 900 | 9.38 |
03:42 ET | 1513 | 9.375 |
03:44 ET | 800 | 9.38 |
03:46 ET | 2887 | 9.375 |
03:48 ET | 4094 | 9.375 |
03:50 ET | 4849 | 9.37 |
03:51 ET | 21840 | 9.365 |
03:53 ET | 2987 | 9.365 |
03:55 ET | 21026 | 9.36 |
03:57 ET | 7573 | 9.36 |
04:00 ET | 137466 | 9.36 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Poseida Therapeutics Inc | 912.3M | -14.7x | --- |
Immatics NV | 936.9M | -12.4x | --- |
Zymeworks Inc | 981.5M | -9.5x | --- |
Abcellera Biologics Inc | 886.1M | -5.0x | --- |
CureVac NV | 695.4M | 6.1x | --- |
Prothena Corporation PLC | 756.0M | -5.7x | --- |
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $912.3M |
---|---|
Revenue (TTM) | $150.9M |
Shares Outstanding | 97.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.64 |
EPS | $-0.63 |
Book Value | $1.08 |
P/E Ratio | -14.7x |
Price/Sales (TTM) | 6.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -41.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.